Company / Net Income
ORAMED PHARMACEUTICALS INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$19.1M
FY2025
5-year range
-$36.6M / $5.1M
FY2021-FY2025
Trend
-474.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -475% YoY in FY2025, a notable deviation from the 9-year average annual change of -68%.
Based on SEC 10-K filings.
-$19M in FY2025.
Improved from -$37M to -$19M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income decreased 474.6% year-over-year.
- Peak net income was recorded in FY2024.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$19.1M | -474.6% |
| FY2024 | $5.1M | +113.9% |
| FY2023 | -$36.6M | -59.0% |
| FY2022 | -$23.0M | -99.7% |
| FY2021 | -$11.5M | +19.8% |
| FY2020 | -$14.4M | -37.0% |
| FY2019 | -$10.5M | +4.4% |
| FY2018 | -$11.0M | -51.6% |
| FY2017 | -$7.2M | -27.0% |
| FY2016 | -$5.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026